<DOC>
	<DOCNO>NCT00000756</DOCNO>
	<brief_summary>To determine safety , tolerance , feasibility adoptive immunotherapy autologous cytotoxic T-lymphocytes ( CTLs ) HIV-infected patient CD4 count 100 400 ; evaluate immunologic , virologic , clinical change 24 week follow infusion study therapy . Freshly isolated peripheral blood lymphocytes HIV-1-seropositive individual frequently lyse autologous HIV-1-expressing cell autologous cell infect vaccinia vector encode HIV-1-specific protein . Administration cytotoxic T lymphocytes ( CTLs ) may help prevent HIV disease progression .</brief_summary>
	<brief_title>Evaluation Safety Tolerance Immunotherapy With Autologous , Ex-Vivo Expanded , HIV-Specific Cytotoxic T-Cells HIV-Infected Patients With CD4+ Counts Between 100-400/mm3</brief_title>
	<detailed_description>Freshly isolated peripheral blood lymphocytes HIV-1-seropositive individual frequently lyse autologous HIV-1-expressing cell autologous cell infect vaccinia vector encode HIV-1-specific protein . Administration cytotoxic T lymphocytes ( CTLs ) may help prevent HIV disease progression . AMENDED 03/28/94 : Patients accrue 25 billion CTL dose . Instead , third cohort receives three infusion 1 billion CTL 5-8 week apart . AMENDED 02/14/94 : Patients infuse 1 5 billion CTL reinfused 1 billion CTL 6-12 month later , follow 12 week reinfusion . ORIGINAL DESIGN : Fifteen patient whose cell show HIV-specific cytotoxic T lymphocyte ( CTL ) response infuse autologous , ex-vivo expand CTLs dose 1 , 5 , 25 billion cell ( five patient per dose level ) . If one three patient give dose develop acute toxicity , additional three patient enter dose . If four patient give dose develop acute toxicity , next low dose designate MTD ( four patient develop acute toxicity first cohort , study terminate ) . Patients evaluate infusion 1 , 2 , 4 , 8 , 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Approved antiretroviral therapy and/or prophylactic PCP therapy , provide change therapy 4 week prior study entry . Other approve treatment HIVrelated disease know affect cellular immune response . GCSF . Erythropoietin . Supportive care acute therapyrelated toxicity . Patients must : HIV infection . CD4 count 100 400 cells/mm3 . No current previously document AIDSrelated opportunistic infection , malignancy , encephalopathy mild Kaposi 's sarcoma . FEV1 &gt; 70 percent , DLCO &gt; 50 percent predict height age ( initial infusion ) . T cell line specific cytotoxicity HIV1 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant autoimmune disease . NonAIDSassociated malignancy . Symptoms cardiac disease . Dyspnea significant exertion . Acute infiltrate chest radiograph . Patients follow prior condition exclude : History significant arrhythmia , infarction , heart failure . History major psychiatric illness . Prior Medication : Excluded within 4 week prior study entry : Systemic immunosuppressive therapy ( i.e. , steroid , cyclosporine , chemotherapy , alphainterferon ) . Therapy acute infection , AIDSrelated opportunistic infection , malignancy . Experimental AIDS therapy . Prior Treatment : Excluded : Potentially immunosuppressive local therapy radiation therapy Kaposi 's sarcoma within 4 week prior study entry . Current substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Immunotherapy , Adoptive</keyword>
	<keyword>Transplantation , Autologous</keyword>
</DOC>